CompletedNot Applicable

Application of Injectable Platelet-Rich Fibrin for the Treatment of Temporomandibular Joint Osteoarthritis

Turkey (Türkiye)36 participantsStarted 2019-04-02

Plain-language summary

The authors designed a randomized, controlled, double-blind clinical trial after the ethical approval by the University Ethics Committee. The patients with temporomandibular joint osteoarthritis (TMJ-OA) randomly assigned one of the two treatment groups: intra-articular injection of injectable platelet-rich fibrin (i-PRF) after arthrocentesis procedure as i-PRF group and arthrocentesis procedure alone as control group. The primary outcome variable was pain levels at preoperatively, and postoperatively at 1st, 2nd, 3rd, 6th and 12th month. The secondary outcome variables included maximum mouth opening (MMO), lateral and protrusive movements.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients with osteoarthritis (OA) of one or two temporomandibular joint (TMJ) * maximum mouth opening less than 35 mm * impeded protrusive and lateral movements * localized pain of the affected joint Exclusion Criteria: * systemic or malignant diseases affecting TMJ-OA assessment * previous invasive or surgical treatments of TMJ unrelated to OA * edentulous patients * pregnancy

What they're measuring

Change of Pain Level

Timeframe: at preoperatively, and postoperatively at 1st, 2nd, 3rd, 6th and 12th month

Trial details

NCT IDNCT04810923

SponsorEge University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-12-02

View on ClinicalTrials.gov More Osteoarthritis trials